MeiraGTx is a clinical-stage genetic medicines company developing viral vector-based therapies using local delivery for inherited and common diseases affecting the eye, radiation-induced xerostomia, and Parkinson's disease, with four late-stage clinical programs and in-house manufacturing capabilities.